In Partnership with

Two patients. Same drug. Same dose. One responds, one doesn’t.

Genetics is often the reason — and pharmacogenomics gives you a way to see it coming instead of discovering it after a failed trial or an adverse event.

We’ll cover:

• The genetics you actually need to interpret a PGx report (no more, no less)
• How variation drives drug metabolism, efficacy, and adverse-event risk
• Where to find trusted guidance — CPIC for acting on results, FDA labeling for the associations behind them
• Real patient cases, including how PGx fits into a workflow you already have

You’ll leave knowing when PGx is worth ordering, how to read the result, and what to do with it.

Presenters

Josiah Allen, PharmD
Dr. Josiah Allen is a clinical pharmacogenomic pharmacist with more than 15 years of experience in pharmacogenomics, precision medicine, clinical research, and implementation. He currently serves as a Pharmacogenomics Pharmacist and PGY2 Clinical Pharmacogenomics Residency Program Director at St. Elizabeth Healthcare. His experience includes clinical practice, education, research, and the development and implementation of PGx programs.

Charles Parks, Chief Executive Officer
Leads Global Clinical Services’ healthcare, clinical support, laboratory, and technology-enabled service initiatives, with a focus on improving healthcare delivery and patient outcomes.

Jeff Williams, Chief Operating Officer
Oversees operations and service delivery at Global Clinical Services, bringing extensive experience in healthcare operations, project management, technology, and process improvement.

Registration

Register